PL197813B1 - Kompozycja farmaceutycznej jednostki dawkowania zawierająca inhibitor fosfodiesterazy i jej zastosowanie - Google Patents

Kompozycja farmaceutycznej jednostki dawkowania zawierająca inhibitor fosfodiesterazy i jej zastosowanie

Info

Publication number
PL197813B1
PL197813B1 PL352629A PL35262900A PL197813B1 PL 197813 B1 PL197813 B1 PL 197813B1 PL 352629 A PL352629 A PL 352629A PL 35262900 A PL35262900 A PL 35262900A PL 197813 B1 PL197813 B1 PL 197813B1
Authority
PL
Poland
Prior art keywords
compound
dosage unit
dose
advice
pde5
Prior art date
Application number
PL352629A
Other languages
English (en)
Polish (pl)
Other versions
PL352629A1 (en
Inventor
William Ernest Pullman
John Steven Whitaker
Original Assignee
Lilly Icos Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22452153&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL197813(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Icos Llc filed Critical Lilly Icos Llc
Publication of PL352629A1 publication Critical patent/PL352629A1/xx
Publication of PL197813B1 publication Critical patent/PL197813B1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Formation And Processing Of Food Products (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Mechanical Treatment Of Semiconductor (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Glass Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
PL352629A 1999-04-30 2000-04-26 Kompozycja farmaceutycznej jednostki dawkowania zawierająca inhibitor fosfodiesterazy i jej zastosowanie PL197813B1 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13203699P 1999-04-30 1999-04-30
PCT/US2000/011129 WO2000066099A2 (en) 1999-04-30 2000-04-26 Compositions comprising phosphodiesterase inhabitors for the treatment of sexual disfunction

Publications (2)

Publication Number Publication Date
PL352629A1 PL352629A1 (en) 2003-08-25
PL197813B1 true PL197813B1 (pl) 2008-04-30

Family

ID=22452153

Family Applications (2)

Application Number Title Priority Date Filing Date
PL352629A PL197813B1 (pl) 1999-04-30 2000-04-26 Kompozycja farmaceutycznej jednostki dawkowania zawierająca inhibitor fosfodiesterazy i jej zastosowanie
PL00339897A PL339897A1 (en) 1999-04-30 2000-04-26 Pharmacological product, pharmacological preparation as well as application of selective pde5 inhibitors

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL00339897A PL339897A1 (en) 1999-04-30 2000-04-26 Pharmacological product, pharmacological preparation as well as application of selective pde5 inhibitors

Country Status (47)

Country Link
EP (2) EP1415652A3 (de)
JP (2) JP2000336043A (de)
KR (2) KR20010020779A (de)
CN (2) CN1196487C (de)
AT (1) ATE251908T1 (de)
AU (3) AU769946C (de)
BE (1) BE1012957A5 (de)
BR (2) BR0010181A (de)
CA (2) CA2307101C (de)
CH (2) CH692478A5 (de)
CO (1) CO5170493A1 (de)
CZ (1) CZ296534B6 (de)
DE (3) DE10021266A1 (de)
DK (2) DK1173181T6 (de)
DZ (1) DZ3171A1 (de)
EA (2) EA005416B1 (de)
ES (2) ES2187234A1 (de)
FI (1) FI20000976L (de)
FR (1) FR2795646B1 (de)
GB (1) GB2351663A (de)
GR (1) GR1003575B (de)
HK (1) HK1041204B (de)
HR (2) HRP20000243A2 (de)
HU (2) HUP0001632A3 (de)
ID (1) ID25704A (de)
IE (1) IE20000315A1 (de)
IL (3) IL135817A0 (de)
IT (1) ITMI20000922A1 (de)
LT (1) LT4758B (de)
LU (1) LU90569B1 (de)
LV (1) LV12560B (de)
MX (2) MXPA00003997A (de)
NL (1) NL1015027C2 (de)
NO (2) NO20002097L (de)
NZ (2) NZ504163A (de)
PE (1) PE20010071A1 (de)
PL (2) PL197813B1 (de)
PT (2) PT102457A (de)
SE (1) SE0001518L (de)
SG (1) SG98384A1 (de)
SI (2) SI1173181T1 (de)
SK (1) SK285415B6 (de)
SV (1) SV2002000055A (de)
TR (1) TR200001132A3 (de)
UA (1) UA72248C2 (de)
WO (1) WO2000066099A2 (de)
ZA (2) ZA200002058B (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2310166T3 (es) * 1999-08-03 2009-01-01 Lilly Icos Llc Composicion farmaceutica que contiene tadalafil.
DE10010612A1 (de) * 2000-03-03 2001-09-27 Merck Patent Gmbh Verwendung von PDE V-Inhibitoren
US20030153575A1 (en) * 2000-06-08 2003-08-14 Orme Mark W. Tetracyclic diketopiperazine compounds as pdev inhibitors
AU2001271948A1 (en) * 2000-08-02 2002-02-13 Lilly Icos Llc Fused heterocyclic derivatives as phosphodiesterase inhibitors
ATE360422T1 (de) * 2001-06-05 2007-05-15 Lilly Icos Llc Tetrazyklische verbindungen als pde5-inhibitoren
GB0129274D0 (en) * 2001-12-06 2002-01-23 Pfizer Ltd Novel kit
US20060205733A1 (en) * 2004-08-26 2006-09-14 Encysive Pharmaceuticals Endothelin a receptor antagonists in combination with phosphodiesterase 5 inhibitors and uses thereof
AU2007230716B2 (en) 2006-03-28 2012-05-03 Javelin Pharmaceuticals, Inc. Formulations of low dose diclofenac and beta-cyclodextrin
US7495024B2 (en) 2006-08-07 2009-02-24 Via Pharmaceuticals, Inc. Phenylalkyl N-hydroxyureas for combating atherosclerotic plaque
DE102007028869A1 (de) 2007-06-22 2008-12-24 Ratiopharm Gmbh Verfahren zur Herstellung eines Arzneimittels enthaltend Tadalafil
DE102009033396A1 (de) 2009-07-16 2011-01-20 Ratiopharm Gmbh Wässrige Lösung und gelatinierte Zusammensetzung umfassend einen Phosphodiesterase-5-Inhibitor sowie diesbezügliche Verfahren und Verwendung
US20110136815A1 (en) 2009-12-08 2011-06-09 Horst Zerbe Solid oral film dosage forms and methods for making same
US10610528B2 (en) 2009-12-08 2020-04-07 Intelgenx Corp. Solid oral film dosage forms and methods for making same
US20110263606A1 (en) * 2010-04-26 2011-10-27 Horst Zerbe Solid oral dosage forms comprising tadalafil
WO2012107092A1 (en) 2011-02-10 2012-08-16 Synthon Bv Pharmaceutical composition comprising tadalafil and a cyclodextrin
RU2013141446A (ru) 2011-02-10 2015-03-20 Синтон Бв Фармацевтическая композиция, содержащая тадалафил и циклодекстрин
EP2672959A1 (de) 2011-02-10 2013-12-18 Synthon BV Granulierte zusammensetzung mit tadalafil und einem sprengmittel
KR102239291B1 (ko) 2013-06-28 2021-04-14 한미약품 주식회사 타다라필 또는 이의 약학적으로 허용가능한 염을 포함하는 저작정 제제
KR101663238B1 (ko) 2013-11-15 2016-10-14 한미약품 주식회사 타다라필 및 암로디핀을 포함하는 복합 고형 제제
JP2019065006A (ja) 2017-09-29 2019-04-25 ハンミ ファーマシューティカルズ カンパニー リミテッド 生産性及び均一性が改善されたタダラフィルを含む固形製剤、及びその製造方法
WO2019154896A1 (de) * 2018-02-07 2019-08-15 Sapiotec Gmbh Pharmazeutische formulierungen, verfahren zum herstellen einer pharmazeutischen formulierung sowie ein arzneimittel umfassend eine solche

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9311920D0 (en) * 1993-06-09 1993-07-28 Pfizer Ltd Therapeutic agents
GB9514465D0 (en) 1995-07-14 1995-09-13 Glaxo Lab Sa Chemical compounds
GB9401090D0 (en) * 1994-01-21 1994-03-16 Glaxo Lab Sa Chemical compounds
GB9423911D0 (en) * 1994-11-26 1995-01-11 Pfizer Ltd Therapeutic agents
GB9511220D0 (en) * 1995-06-02 1995-07-26 Glaxo Group Ltd Solid dispersions
GB9514473D0 (en) * 1995-07-14 1995-09-13 Glaxo Lab Sa Chemical compounds
GB9514464D0 (en) * 1995-07-14 1995-09-13 Glaxo Lab Sa Medicaments
HUP9901478A3 (en) 1996-05-10 1999-11-29 Icos Corp Bothell Carboline derivatives, their use, production thereof and medicaments containing the same
PL336586A1 (en) * 1997-04-25 2000-07-03 Pfizer Pyrazoylpyrimidinones inhibiting the cyclic guanosine 3',5'-monophosphate phosphodiesterase of type 5 (cgmp pde5) for treating sexual disorders
AU4068599A (en) * 1998-05-20 1999-12-06 Schering Corporation Combination of phentolamine and cyclic gmp phosphodiesterase inhibitors for the treatment of sexual dysfunction
AU1025899A (en) 1998-09-16 2000-04-03 Icos Corporation Carboline derivatives as cgmp phosphodiesterase inhibitors
US6743443B1 (en) * 1998-10-05 2004-06-01 Eisai Co., Ltd. Tablets immediately disintegrating in the oral cavity
CA2362918A1 (en) * 1999-03-08 2000-09-14 Elizabeth Stoner Methods and compositions for treating erectile dysfunction
US6451807B1 (en) * 1999-04-30 2002-09-17 Lilly Icos, Llc. Methods of treating sexual dysfunction in an individual suffering from a retinal disease, class 1 congestive heart failure, or myocardial infarction using a PDE5 inhibitor
US6613768B1 (en) * 1999-04-30 2003-09-02 Lilly Icos Llc Treatment of female arousal disorder

Also Published As

Publication number Publication date
DE10021266A1 (de) 2000-11-16
EP1415652A3 (de) 2004-05-12
SV2002000055A (es) 2002-07-03
AU3012900A (en) 2000-11-02
EA200000355A3 (ru) 2001-02-26
IE20000315A1 (en) 2001-03-07
PT102457A (pt) 2000-11-30
FR2795646A1 (fr) 2001-01-05
NZ514882A (en) 2003-08-29
ZA200108900B (en) 2003-03-26
DK1173181T6 (en) 2015-04-27
CA2371684C (en) 2007-10-23
CZ296534B6 (cs) 2006-04-12
MXPA01010837A (es) 2002-11-07
CZ20013879A3 (cs) 2002-04-17
SG98384A1 (en) 2003-09-19
CH1173181H1 (de) 2019-07-15
HK1041204A1 (en) 2002-07-05
NO20015275D0 (no) 2001-10-29
KR100577057B1 (ko) 2006-05-10
HUP0200912A2 (en) 2002-08-28
ES2187234A1 (es) 2003-05-16
CA2307101A1 (en) 2000-10-30
ITMI20000922A1 (it) 2001-10-26
TR200001132A2 (tr) 2001-01-22
CO5170493A1 (es) 2002-06-27
DK200000677A (da) 2000-10-31
HK1041204B (en) 2004-03-05
KR20020008396A (ko) 2002-01-30
ID25704A (id) 2000-11-02
JP4975214B2 (ja) 2012-07-11
LV12560B (en) 2001-04-20
DE20007861U1 (de) 2000-08-24
HUP0200912A3 (en) 2003-07-28
CA2371684A1 (en) 2000-11-09
NO20015275L (no) 2001-12-06
PE20010071A1 (es) 2001-03-22
ITMI20000922A0 (it) 2000-04-26
FI20000976A7 (fi) 2000-10-30
TR200001132A3 (tr) 2001-01-22
EA200000355A2 (ru) 2000-10-30
CH692478A5 (de) 2002-07-15
JP2002543116A (ja) 2002-12-17
EP1173181B1 (de) 2003-10-15
AU4490800A (en) 2000-11-17
ES2208317T7 (es) 2015-09-15
HU230369B1 (hu) 2016-03-29
IL146098A0 (en) 2002-07-25
PT1173181E (pt) 2004-02-27
DE60005940T3 (de) 2015-08-27
DE60005940D1 (de) 2003-11-20
HU0200912D0 (en) 2002-04-29
FI20000976A0 (fi) 2000-04-26
SE0001518L (sv) 2000-10-31
IL146098A (en) 2007-06-03
NZ504163A (en) 2001-11-30
ES2208317T3 (es) 2004-06-16
LV12560A (en) 2000-11-20
ZA200002058B (en) 2000-11-02
NO322013B3 (no) 2017-11-06
LT2000035A (lt) 2000-11-27
GB0010199D0 (en) 2000-06-14
SI20361A (sl) 2001-04-30
PL339897A1 (en) 2000-11-06
CN1384746A (zh) 2002-12-11
AU2004201988A1 (en) 2004-06-10
BR0010181A (pt) 2003-02-25
CN1292264A (zh) 2001-04-25
NL1015027A1 (nl) 2000-10-31
LT4758B (lt) 2001-02-26
BR0003046A (pt) 2002-07-23
FR2795646B1 (fr) 2002-08-16
KR20010020779A (ko) 2001-03-15
PL352629A1 (en) 2003-08-25
HUP0001632A2 (hu) 2001-05-28
ATE251908T1 (de) 2003-11-15
MXPA00003997A (es) 2002-03-08
SI1173181T1 (en) 2004-04-30
GB2351663A (en) 2001-01-10
CA2307101C (en) 2003-01-28
EP1173181A2 (de) 2002-01-23
SE0001518D0 (sv) 2000-04-26
WO2000066099A2 (en) 2000-11-09
UA72248C2 (en) 2005-02-15
GR1003575B (el) 2001-05-14
BE1012957A5 (fr) 2001-06-05
HRP20010778B1 (en) 2005-04-30
EA200101008A1 (ru) 2002-04-25
NO20002097D0 (no) 2000-04-25
EP1173181B3 (de) 2015-03-25
AU769946C (en) 2005-01-13
HUP0001632A3 (en) 2001-12-28
WO2000066099A3 (en) 2001-01-18
SK15632001A3 (sk) 2002-02-05
HRP20010778A2 (en) 2002-12-31
SK285415B6 (sk) 2007-01-04
JP2000336043A (ja) 2000-12-05
CN1196487C (zh) 2005-04-13
LU90569B1 (fr) 2002-02-27
DZ3171A1 (de) 2000-11-09
DE60005940T2 (de) 2004-07-29
DK1173181T3 (da) 2004-02-16
GR20000100153A (el) 2000-12-29
EA005416B1 (ru) 2005-02-24
HU0001632D0 (en) 2000-06-28
NL1015027C2 (nl) 2001-02-14
NO322013B1 (no) 2006-08-07
EP1415652A2 (de) 2004-05-06
IL135817A0 (en) 2001-05-20
AU769946B2 (en) 2004-02-12
FI20000976L (fi) 2000-10-30
NO20002097L (no) 2001-10-26
HRP20000243A2 (en) 2001-12-31

Similar Documents

Publication Publication Date Title
US6943166B1 (en) Compositions comprising phosphodiesterase inhabitors for the treatment of sexual disfunction
PL197813B1 (pl) Kompozycja farmaceutycznej jednostki dawkowania zawierająca inhibitor fosfodiesterazy i jej zastosowanie
US6451807B1 (en) Methods of treating sexual dysfunction in an individual suffering from a retinal disease, class 1 congestive heart failure, or myocardial infarction using a PDE5 inhibitor
US20010053780A1 (en) Daily treatment for erectile dysfunction using a PDE5 inhibitor
HK1065485A (en) Composition comprising phosphodiesterase inhibitors for the treatment of sexual dysfunction
CZ20001536A3 (cs) Orální léčivo